Follow us on LinkedIn, X, Facebook and Instagram. Visit us at https://www.bio.org/For biotech companies, the valley of death describes the difficult path from initial discovery to FDA approval and commercialization. It's a treacherous journey—one that even promising innovations often don't complete. Adequate funding, regulatory hurdles and the immense complexity of the biotech landscape are among the never-ending challenges faced by early stage biotechs. In this episode we talk with two biotech executives about what it’s like to struggle and survive in this rough-and-tumble industry.